[PDF][PDF] Anti–cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment
L Fong, EJ Small - Journal of clinical oncology, 2008 - Citeseer
L Fong, EJ Small
Journal of clinical oncology, 2008•CiteseerPurpose To evaluate the emerging role of immunomodulatory antibodies in cancer
treatment. Antibodies (ipilimumab and tremelimumab) targeting cytotoxic T-lymphocyte
antigen-4 (CTLA-4), an inhibitory molecule on T cells, represent the vanguard of these new
drugs.
treatment. Antibodies (ipilimumab and tremelimumab) targeting cytotoxic T-lymphocyte
antigen-4 (CTLA-4), an inhibitory molecule on T cells, represent the vanguard of these new
drugs.
Purpose
To evaluate the emerging role of immunomodulatory antibodies in cancer treatment. Antibodies (ipilimumab and tremelimumab) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), an inhibitory molecule on T cells, represent the vanguard of these new drugs.
Citeseer